Market Recap — August 27, 2026
Recap of insider activity, SEC filings, and market-moving news for August 27, 2026.
Last generated Sep 17, 2026, 10:50 PM ET
Top Importance Today
Filings and news with the highest AI-ranked importance score.
BioXcel Therapeutics Files Chapter 11 Bankruptcy With $100M-$500M Liabilities
FDA Approves Roivant's LISRAYA as First Targeted Therapy for Dermatomyositis
Solstice Terminates $14.5B Element Solutions Merger, Authorizes $500M Buyback
Second Nasdaq Delisting Notice Hits SOBR Safe as Equity Deficiency Compounds Bid Price Failure
Element Solutions' $14.5B Merger with Solstice Terminated
Kazia Reports 100% Clinical Benefit Rate in Stage IV TNBC; Files Investor Deck for Proposed Offering
Bleichroeder Completes $2.0B Pasqal Merger, New Entity to Trade as PSQL
Workday Reports Strong Q2 Results, Raises FY27 Margin Guidance, Authorizes New $4B Buyback
Rein Therapeutics Faces Nasdaq Delisting Notice Over Sub-$1.00 Bid Price
Ulta Beauty Q2 EPS Beats, Raises FY26 Guidance on Strong Sales
Accuray 10-K: $49M Loss, Adverse ICFR Opinion, and Covenant Breach Confirmed
Workday Q2 Beats: Revenue Up 12.8%, Raises FY27 Margin Guidance to 31%
Largest Open-Market Insider Buys
Form 4 open-market purchases ranked by dollar amount.
Largest Open-Market Insider Sells
Form 4 open-market sales ranked by dollar amount.
Notable 8-Ks and News
Material events and breaking news with importance score 6 or higher.
BioXcel Therapeutics Files Chapter 11 Bankruptcy With $100M-$500M Liabilities
FDA Approves Roivant's LISRAYA as First Targeted Therapy for Dermatomyositis
Solstice Terminates $14.5B Element Solutions Merger, Authorizes $500M Buyback
Second Nasdaq Delisting Notice Hits SOBR Safe as Equity Deficiency Compounds Bid Price Failure
Element Solutions' $14.5B Merger with Solstice Terminated
Bleichroeder Completes $2.0B Pasqal Merger, New Entity to Trade as PSQL
Rein Therapeutics Faces Nasdaq Delisting Notice Over Sub-$1.00 Bid Price
Ulta Beauty Q2 EPS Beats, Raises FY26 Guidance on Strong Sales
Workday Q2 Beats: Revenue Up 12.8%, Raises FY27 Margin Guidance to 31%
Paxalisib Shows 100% Clinical Benefit in Advanced TNBC, 83% Objective Response
Form 144 Notices
Notices that restricted shares may be sold soon — often a precursor to insider selling.
Day boundary: 00:00 ET (America/New_York). Filings accepted late may appear in the next day's recap.